– At Almost Four Years of Follow-up in the Pivotal ZUMA-2 Study, Median Overall Survival was 46.4 Months, Supporting Long-Term Response in Adult Patients with Relapsed/Refractory (R/R) Mantle Cell ...

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

Microsoft Surface Laptop Go 2 is rumored to be released in June. Here's what the leak says about its features. Microsoft As Windows Central initially reported last Tuesday, Apr. 12, the upcoming ...

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts After a median follow-up of ...

ZUMA-2 is a single-arm, international multicenter (US and Europe), open-label Phase 2 study involving 74 enrolled/leukapheresed adult patients (≥18 years old) with MCL whose disease is refractory to ...